Methylmalonic acidemia results from decreased activity of methylalonyl-CoA mutase, an enzyme required for the catabolism of four amino acids. A cobalamin (vitamin B12) compound is required as coenzyme. Several inherited mutations of the mutase apoenzyme or of cobalamin coenzyme synthesis have been identified. Clinical disease is most commonly recognized as a severe protein intolerance state although a wide range of symptoms has been appreciated. Current therapy emphasizes strict dietary management and use of vitamin B12 in cobalamin responsive patients.
No takes yet. Share an insight, caveat, or question.
Mahoney et al. (1987) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: